記憶・認知障礙的治療動向

記憶・認知障礙的治療動向 是由出版商BCC Research在2009年04月所出版的。 這份英文市場調查報告書價格從美金4850起跳。

簡介

目錄

Abstract

This Report:

• Details the disease states that lead to memory & cognition impairment
• Provides forecasts and detail relative to the products available to treat this condition.
• Provides definition and market structure, including discussion on cognition and diagnostic tests
• Analyzes market size and key players
• Identifies worldwide industry structure, including growth drivers and obstacles, and related technology considerations
• Details primary and secondary applications, legislation and the regulatory environment, related deals, and partnerships, patent analysis, and company profiles.
• Analyzes the market outlook, trends, and challenges.

Table of Contents

Chapter-1: SUMMARY 6

• SUMMARY TABLE WORLDWIDE POTENTIAL MARKET FOR MEMORY/COGNITION THERAPEUTICS, BY DISEASE AREA, THROUGH 2014 ($ MILLIONS) 4
• SUMMARY FIGURE WORLDWIDE MEMORY/COGNITION THERAPEUTICS MARKET, BY DISEASE AREA, 2008 (%) 5
• DISEASE STATES 6
• DISEASE STATES (CONTINUED) 7
• TREATMENTS IN DEVELOPMENT 8
• THE FUTURE 9

Chapter-2: OVERVIEW 10

• PRIMARY 20
• TABLE 3 DEMENTIA RATE BY UNDERLYING DISEASE STATE (%) 20
• FIGURE 1 DEMENTIA CASES BY UNDERLYING DISEASE STATE (%) 21
• SECONDARY 22
• MEDICATION-RELATED 22
• SUBSTANCE ABUSE 23
• CREUTZFELDT JAKOB DISEASE 23
• Creutzfeldt Jakob Disease (Continued) 24
• ADHD 25
• MULTIPLE SCLEROSIS 25
• Multiple Sclerosis (Continued) 26
• INFECTION 27
• METABOLIC DISORDERS 27
• BRAIN TUMORS 28
• CABG 28
• TABLE 4 PERCENT OF PATIENTS WITH DEMENTIA/COGNITIVE DEFICIT (%) 28
• PRIMARY 28
• ALZHEIMER' S DISEASE 28
• TABLE 5 WORLDWIDE DISEASE PREVALENCE: ALZHEIMER' S DISEASE (%) 29
• TABLE 6 EXISTING TREATMENTS: ALZHEIMER' S DISEASE 29
• Role of the Cholinergic System 29
• Role of Beta-Amyloid Protein 30
• TABLE 7 TREATMENT FORECAST FOR ALZHEIMER' S DISEASE, THROUGH 2014 ($ MILLIONS) 31
• FIGURE 2 TREATMENT FORECAST FOR ALZHEIMER' S DISEASE, 2007-2014 ($ MILLIONS) 31
• VASCULAR DEMENTIA 32
• TABLE 8 WORLDWIDE DISEASE PREVALENCE: VASCULAR DEMENTIA (%) 32
• TABLE 9 EXISTING TREATMENTS: VASCULAR DEMENTIA 32
• Cause 33
• VCIND 34
• Binswanger' s Disease 34
• Multi-Infarct Dementia 34
• Treatment 35
• TABLE 10 TREATMENT FORECAST FOR VASCULAR DEMENTIA, THROUGH 2014 ($ MILLIONS) 35
• FIGURE 3 TREATMENT FORECAST FOR VASCULAR DEMENTIA, 2007-2014 ($ MILLIONS) 36
• Counseling and Psychotherapy 37
• Pharmacotherapy 37
• Outlook 38
• LEWY BODY DEMENTIA 38
• TABLE 11 WORLDWIDE DISEASE PREVALENCE: LEWY BODY DEMENTIA (%) 39
• Treatment 39
• TABLE 12 EXISTING TREATMENTS: LBD 40
• Outlook 40
• TABLE 13 TREATMENT FORECAST FOR LBD, THROUGH 2014 ($ MILLIONS) 40
• FIGURE 4 TREATMENT FORECAST FOR LBD, 2007-2014 ($ MILLIONS) 41
• PARKINSON' S DISEASE 41
• Parkinson' s Disease (Continued) 42
• Other Parkinsonism Syndromes 43
• Recognizing Other Causes of Parkinsonism 43
• Medication-Induced Parkinsonism 44
• Corticobasal Degeneration (CBD) 44
• Multiple System Atrophy (MSA) 44
• Multiple System Atrophy (Continued) 45
• Multiple System Atrophy (Continued) 46
• SCHIZOPHRENIA 47
• Schizophrenia (Continued) 48
• Schizophrenia (Continued) 49
• TABLE 14 WORLDWIDE DISEASE PREVALENCE: SCHIZOPHRENIA (%) 50
• Treatment 50
• TABLE 15 EXISTING TREATMENTS: SCHIZOPHRENIA 51
• TABLE 16 TREATMENT FORECAST FOR COGNITION IN SCHIZOPHRENIA (CIAS), THROUGH 2014 ($ MILLIONS) 51
• FIGURE 5 TREATMENT FORECAST FOR COGNITION IN SCHIZOPHRENIA (CIAS), 2007-2014 ($ MILLIONS) 52
• Treatment (Continued) 53
• Outlook 54
• MCI/AAMI 54
• TABLE 17 WORLDWIDE DISEASE PREVALENCE: MCI/AAMI (%) 55
• TABLE 18 EXISTING TREATMENTS: MCI/AAMI 55
• TABLE 19 TREATMENT FORECAST FOR MCI/AAMI, THROUGH 2014 ($ MILLIONS) 55
• FIGURE 6 TREATMENT FORECAST FOR MCI/AAMI, 2007-2014 ($ MILLIONS) 56
• HUNTINGTON' S DISEASE 56
• Demographics 57
• TABLE 20 WORLDWIDE DISEASE PREVALENCE: HUNTINGTON' S DISEASE (%) 57
• TABLE 21 EXISTING TREATMENTS: HUNTINGTON' S DISEASE 57
• Demographics (Continued) 58
• Treatment 59
• TABLE 22 TREATMENT FORECAST FOR HUNTINGTON' S DISEASE, THROUGH 2014 ($ MILLIONS) 60
• FIGURE 7 TREATMENT FORECAST FOR HUNTINGTON' S DISEASE, 2007-2014 ($ MILLIONS) 61
• HIV-RELATED MEMORY AND COGNITION EFFECTS 61
• TABLE 23 WORLDWIDE DISEASE PREVALENCE: HIV-RELATED (%) 62
• TABLE 24 EXISTING TREATMENTS: HIV-RELATED 63
• TABLE 25 TREATMENT FORECAST FOR HIV-RELATED, THROUGH 2014 ($ MILLIONS) 63
• FIGURE 8 TREATMENT FORECAST FOR HIV-RELATED, 2007-2014 ($ MILLIONS) 64
• GENETIC DISEASES 64
• TABLE 26 WORLDWIDE DISEASE PREVALENCE: GENETIC DISEASES (%) 64
• TABLE 27 EXISTING TREATMENTS: GENETIC DISEASES 65
• TABLE 28 TREATMENT FORECAST FOR GENETIC DISEASES: COGNITION ONLY, THROUGH 2014 ($ MILLION) 65
• FIGURE 9 TREATMENT FORECAST FOR GENETIC DISEASES, 2007-2014 ($ MILLIONS) 66
• Pick' s Disease 66
• Krabbe Disease 67
• Krabbe Disease (Continued) 68

Chapter-3: APPLICATIONS 49

Chapter-4: MECHANISMS OF ACTION 31

• MECHANISMS OF ACTION 69
• TABLE 29 MARKETED TREATMENTS: ALL DISEASES 70
• COMMON MECHANISMS 71
• CHOLINESTERASE INHIBITORS 71
• TABLE 30 CHOLINESTERASE INHIBITORS 71
• NMDA Antagonists 71
• TABLE 31 NMDA ANTAGONISTS 72
• Nicotinics 72
• TABLE 32 NICOTINIC ACETYLCHOLINE ANTAGONISTS 73
• Calcineurins 73
• TABLE 33 CALCINEURINS 73
• GABA Modulators 74
• TABLE 34 ANTI-EPILEPTIC/GABA MODULATORS 74
• Hormones 75
• TABLE 35 HORMONES 75
• OTHER MECHANISMS 75
• COGNITION ENHANCERS IN DEVELOPMENT 76
• DRUGS FOR DISEASE MODIFICATION 76
• Secretase Inhibitors 76
• Metal Chelation 76
• Vaccines 76
• Statins 76
• Neurotransmitter Targets 77
• NSAIDS 77
• Antioxidants 77
• Hormones 78
• Other Agents 78
• TABLE 36 OVERVIEW OF MEMORY/COGNITION TREATMENTS 78
• TABLE 36 (CONTINUED) 79
• TABLE 37 DEVELOPMENT PIPELINE OF MEMORY/COGNITION DRUGS, BY DEVELOPMENT STATUS 79
• TABLE 37 (CONTINUED) 80
• TABLE 37 (CONTINUED) 81
• TABLE 37 (CONTINUED) 82
• TABLE 37 (CONTINUED) 83
• TABLE 37 (CONTINUED) 84
• TABLE 37 (CONTINUED) 85
• FIGURE 10 DEVELOPMENT PIPELINE OF MEMORY/COGNITION DRUGS: NUMBER OF PROGRAMS AT EACH CLINICAL STAGE 85
• Glutamate 86
• Calcium Channels 86
• Maxi-K Channels 86
• CREB and Phosphodiesterase 87
• Acetylcholine 87
• Dopamine 87
• Serotonin 88
• GABA 88
• The Cannabinoid System 88
• Histamine 89
• Neurohormones and Neuropeptides 89
• Other Molecular Targets 89
• Genome and Stem Cells 90
• FUTURE COGNITION ENHANCERS 91
• Changes in Society 91
• Increasing Knowledge 91
• Scientific Limitations 92
• Implications 93
• Potential Benefits and Harms 93
• Health Economics 94
• Regulation, Ethics, and Society 94
• TABLE 38 OTC TREATMENTS/NATURAL PRODUCTS 95
• OTC TREATMENTS 96
• Ginkgo 97
• GENE THERAPY 98
• STIMULANTS 98
• Stimulants (Continued) 99

Chapter-5: WORLDWIDE INDUSTRY STRUCTURE 24

• GROWTH DRIVERS 100
• TABLE 39 TOP-SELLING MEMORY AND COGNITION DRUGS ($ MILLIONS) 100
• AGING POPULATION 100
• Aging Population (Continued) 101
• OFF-LABEL USE 102
• UNDERSTANDING OF MECHANISMS 103
• Transcranial Magnetic Stimulation 104
• Genetic Modifications 105
• GROWTH OBSTACLES 105
• UNDERSTANDING OF MECHANISMS 106
• TABLE 40 CLINICAL SUCCESS RATES BY THERAPEUTIC AREA (%) 106
• FIGURE 11 CLINICAL SUCCESS RATES BY THERAPEUTIC AREA (%) 106
• CO-MORBID DISEASE STATES 107
• ACCEPTANCE OF MEMORY AND COGNITION AS TREATABLE CONDITIONS 107
• TREATMENT OF CHILDREN 107
• Treatment of Children (Continued) 108
• KEY COMPETITIVE FACTORS 109
• PRODUCT LAUNCH 109
• LIFE CYCLE MANAGEMENT 109
• INDUSTRY LEADERS 110
• MERCK 110
• TABLE 41 MERCK MEMORY AND COGNITION PIPELINE 110
• ROCHE 110
• TABLE 42 ROCHE MEMORY AND COGNITION PIPELINE 110
• PFIZER 111
• TABLE 43 PFIZER MEMORY AND COGNITION PIPELINE 111
• SHIRE 111
• TABLE 44 SHIRE MEMORY AND COGNITION PIPELINE 111
• CEPHALON 112
• TABLE 45 CEPHALON MEMORY AND COGNITION PIPELINE 112
• PAYORS 112
• PAYORS (CONTINUED) 113
• INTERNATIONAL ASPECTS 114
• TABLE 46 PER CAPITA GOVERNMENT EXPENDITURE ON HEALTHCARE BY COUNTRY, THROUGH 2006 ($ MILLIONS) 115
• BIOTECHNOLOGY CLUSTERS 116
• LEGISLATION AND REGULATORY ENVIRONMENT 116
• VALIDATED TARGETS 116
• LACK OF BIOMARKERS 116
• TRANSLATIONAL MEDICINE 117
• REIMBURSEMENT 118
• SCHEDULING STATUS 119
• MEMORY AND COGNITION AS A STAND-ALONE INDICATION 119
• RELATED DEALS AND PARTNERSHIPS 119
• RELATED DEALS AND PARTNERSHIPS (CONTINUED) 120
• TABLE 47 RELATED DEALS AND PARTNERSHIPS, 2002-2008 121
• TABLE 47 (CONTINUED) 122
• TABLE 47 (CONTINUED) 123

Chapter-6: PATENT ANALYSIS 19

• INTRODUCTION 124
• TRENDS BY COUNTRY 124
• TABLE 48 PATENT ANALYSIS MAJOR U.S. PATENT HOLDERS IN MEMORY/COGNITION DISORDERS 124
• FIGURE 12 MAJOR PATENT HOLDERS BY ASSIGNEE (%) 125
• TRENDS BY ASSIGNEE 125
• TRENDS BY TECHNOLOGY 126
• TABLE 49 U.S. PATENT APPLICATIONS 127
• TABLE 49 (CONTINUED) 128
• TABLE 49 (CONTINUED) 129
• TABLE 49 (CONTINUED) 130
• TABLE 49 (CONTINUED) 131
• TABLE 49 (CONTINUED) 132
• TABLE 49 (CONTINUED) 133
• TABLE 49 (CONTINUED) 134
• TABLE 50 U.S. PATENTS GRANTED 135
• TABLE 50 (CONTINUED) 136
• TABLE 50 (CONTINUED) 137
• TABLE 50 (CONTINUED) 138
• TABLE 50 (CONTINUED) 139
• TABLE 50 (CONTINUED) 140
• TABLE 50 (CONTINUED) 141
• TABLE 50 (CONTINUED) 142

Chapter-7: OUTLOOK: TRENDS AND CHALLENGES 4

• GENERAL TRENDS 143
• GENERAL TRENDS (CONTINUED) 144
• ETHICAL IMPLICATIONS 145
• ETHICAL IMPLICATIONS (CONTINUED) 146

Chapter-8: COMPANY PROFILES 11

• ACADIA PHARMACEUTICALS 147
• ACCERA, INC. 147
• ACUMEN PHARMACEUTICALS 147
• ALLON THERAPEUTICS (FKA NEURODISCOVERY) 147
• ALZHYME PTY 148
• AMARIN PHARMACEUTICALS 148
• ASTRAZENECA 148
• BRAINCELLS, INC. 149
• COGNITION PHARMACEUTICALS 149
• COLUCID PHARMACEUTICALS 149
• COMENTIS 149
• CORTEX PHARMACEUTICALS 150
• ENVIVO PHARMACEUTICALS 150
• GALENEA 150
• GLAXOSMITH KLINE 151
• HELICON THERAPEUTICS 151
• INTELLECT NEUROSCIENCES 151
• INTRA-CELLULAR THERAPIES 151
• IPSEN 152
• LEXICON PHARMACEUTICALS 152
• MEDIVATION 152
• MEMORY PHARMACEUTICALS 152
• MERCK 153
• MERCKSERONO 153
• MITHRIDION 153
• NEUREN PHARMACEUTICALS 153
• NEUROSEARCH 153
• NEURO-HITECH 154
• NEWRON PHARMACEUTICALS 154
• NOVARTIS 154
• PFIZER 154
• PRANA BIOTECHNOLOGY 155
• PSYCHOGENICS 155
• SANOFI-AVENTIS 155
• SATORI PHARMACEUTICALS 155
• SCIELE PHARMA 155
• SEASIDE THERAPEUTICS 156
• SHIRE 156
• TAKEDA 156
• TARGACEPT 156
• TAURX THERAPEUTICS 156
• TEVA PHARMACEUTICALS 157
• VOYAGER PHARMACEUTICAL / DURAMED 157
• WYETH 157

Chapter-9: APPENDIX 11

• COMPANY LISTING 158
• ACADIA PHARMACEUTICALS, INC. 158
• ACCERA, INC. 158
• ACUMEN PHARMACEUTICALS, INC. 158
• ALLON THERAPEUTICS, INC. 159
• ALZHYME, LTD. 159
• AMARIN CORP PLC. 159
• AMARIN PHARMA INC. 159
• ASTRAZENECA 160
• BRAINCELLS, INC. 160
• COGNITION PHARMACEUTICALS LLC 160
• COGNITIVE PHARMACEUTICALS LTD 160
• COLUCID PHARMACEUTICALS 160
• COMENTIS (FKA ATHENAGEN) 160
• CORTEX PHARMACEUTICALS, INC. 15231 BARRANCA PARKWAY 161
• ENVIVO PHARMACEUTICALS 161
• GALENEA CORP. 161
• GLAXOSMITHKLINE 161
• HELICON THERAPEUTICS, INC. 161
• INTELLECT NEUROSCIENCES, INC. 162
• INTRA-CELLULAR THERAPIES 162
• IPSEN 162
• LEXICON PHARMACEUTICALS 162
• MEDIVATION, INC. 163
• MEMORY PHARMACEUTICALS 163
• MERCK & CO., INC. 163
• MERCKSERONO 163
• MITHRIDION 163
• NEUREN PHARMACEUTICALS, LTD 164
• NEUROSEARCH A/S 164
• NEURO-HITECH, INC. 164
• NEWRON 164
• NOVARTIS 165
• PFIZER 165
• PRANA 165
• PSYCHOGENICS, INC. 165
• SANOFI-AVENTIS 165
• SATORI PHARMACEUTICALS 165
• SCIELE PHARMA 166
• SEASIDE THERAPEUTICS 166
• SHIRE 166
• TAKEDA 166
• TARGACEPT, INC. 167
• TAURX THERAPEUTICS LTD. 167
• TEVA PHARMACEUTICALS 167
• VOYAGER PHARMACEUTICALS 167
• WYETH PHARMACEUTICALS 167
• Wyeth Pharmaceuticals (Continued) 168

相關商品

矚目市場調查報告書

全套市場調查報告定期訂閱

Market Research Report Subscription

神經疾病相關市場調查報告書

疼痛治療藥市場的發展：侵害受容性及神經性疼痛治療藥的開發
Evolution in the Pain Therapy Drugs Market: Nociceptive and Neuropathic Drug Development
價格 : US $ 2265
出版日期 : 2012年01月

神經保護：醫療藥品・市場・企業
Neuroprotection - Drugs, Markets and Companies
價格 : US $ 5000
出版日期 : 2012年01月

阿茲海默症：新藥・市場・企業
Alzheimer disease - new drugs, markets and companies
價格 : US $ 3500
出版日期 : 2012年01月

BCC Research發行的製藥相關市場調查報告書

全球的肝臟疾病治療藥市場

Liver Disease Treatments: The Global Market

價格 : US $ 4850

出版日期 : 2012年01月

2011年醫療市場調査評論

2011 Healthcare Research Review

價格 : US $ 850

出版日期 : 2012年01月

肺部給藥系統:技術和全球市場

Pulmonary Drug Delivery Systems: Technologies and Global Markets

價格 : US $ 4850

出版日期 : 2012年01月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!